A new combination treatment for non-small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called ALK202, given with other medicines, to see if it is safe and works for people with non-small cell lung cancer. It targets certain proteins on cancer cells, and doctors will check your tumor for those markers to see if you might benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC), a common type of lung cancer.
- You are 18 to 75 years old.
- You can provide a sample of your tumor (from a prior biopsy or a new one) so doctors can test it for certain markers like EGFR, c-MET, and PD-L1.
- You must have at least one tumor that can be measured on a scan.
- You have not had a previous treatment with an ADC drug that targets EGFR or MET, or that uses a type of chemotherapy called topoisomerase I inhibitor.
- You must be expected to live for at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ALK201 combined with an immunotherapy drug (ivonescimab) for people with squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and is safe.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This study tests a new combination of drugs for advanced non-small cell lung cancer that has stopped responding to the first standard treatment. It is specifically for people whose tumors have certain gene changes (EGFR, ALK, or ROS1). The goal is to see if this combination can help control the cancer.
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.